In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

In­cyte’s mon­o­clon­al an­ti­body Mon­ju­vi re­duced cer­tain fol­lic­u­lar lym­phoma pa­tients’ risk of pro­gres­sion, re­lapse or death by 57% com­pared to place­bo, the com­pa­ny an­nounced Mon­day. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER